2 research outputs found
A HeatâActivated DrugâDelivery Platform Based on Phosphatidylâ(oligo)âglycerol Nanocarrier for Effective Cancer Treatment
The potential of cancer drugs is not fully exploited due to low tumor uptake and occurrence of systemic side effects, limiting maximum tolerated dose. Actively targeted nanocarriers improve efficacy while minimizing offâtarget toxicity. Herein, it is the first time a drugâdelivery platform for heatâtriggered intravascular drug release is described, based on synthetic phosphatidylâ(oligo)âglycerols from organic synthesis to preclinical investigation in feline patients. For the nanocarrier formulated doxorubicin (DOX), superior tumor drug delivery and antitumor activity compared with free DOX, conventional liposomal DOX (Caelyx), and temperatureâsensitive lysolipidâcontaining DOXâliposomes in rat sarcoma are demonstrated. In a comparative oncological study with neoadjuvant treatment of feline sarcoma, a metabolic response determined with 18âFâFDGâpositron emission tomography/magnetic resonance imaging (PET/MRI) and histopathological response after tumor resection are significantly better compared with free DOX, potentially by overcoming drug resistance based on improved intratumoral drug distribution. This novel drugâdelivery platform has great potential for the treatment of locally advanced tumors in humans